Immunoglobulin for myasthenia gravis

Area of Science:

• Neurology
• Immunology
• Clinical Trials

Background:

• Immunoglobulin therapy is used for neuroimmunological conditions like myasthenia gravis (MG).
• Evidence for immunoglobulin's efficacy in MG is uncertain.
• Generalized MG requires effective treatment options.

Purpose of the Study:

• To assess the benefits and harms of immunoglobulin in generalized MG.
• Compare intravenous immunoglobulin (IVIg) versus subcutaneous immunoglobulin (SCIg).
• Compare immunoglobulin (any route) versus placebo, plasma exchange (PLEX), corticosteroids, or other treatments.

Main Methods:

• Included parallel and cross-over randomized controlled trials (RCTs).
• Searched multiple databases including Cochrane, MEDLINE, Embase, and ClinicalTrials.gov.
• Assessed risk of bias using RoB 2 tool and certainty of evidence using GRADE.

Main Results:

• Low-certainty evidence suggests IVIg may offer slight medium-term symptom improvement versus placebo, not clinically significant.
• Moderate-certainty evidence indicates IVIg increases headache incidence compared to placebo.
• Very low to low-certainty evidence suggests IVIg may be less effective than PLEX for short-term symptom improvement and may prolong hospitalization.

Conclusions:

• Current evidence for IVIg in MG is of low to very low certainty.
• High-quality trials are needed, including comparisons of SCIg and newer therapies.
• IVIg offers limited benefits for MG and is associated with increased headaches and potentially longer hospital stays.